Masato Homma Selected Research

Tachycardia (Tachyarrhythmias)

1/2022	Increased serum amiodarone concentration in hypertriglyceridemic patients: Effects of drug distribution to serum lipoproteins.
12/2020	Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10.
10/2016	β1-Adrenergic receptor Arg389Gly polymorphism affects the antiarrhythmic efficacy of flecainide in patients with coadministration of β-blockers.
8/2015	Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity.
7/2013	SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients.
11/2012	CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis.
7/2009	Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism.
10/2007	Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia.
11/2006	Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia.
1/2005	Assessment of serum flecainide trough levels in patients with tachyarrhythmia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masato Homma Research Topics

Disease

13	Tachycardia (Tachyarrhythmias) 01/2022 - 08/2002
5	Liddle Syndrome 01/2021 - 10/2006
5	Anemia 01/2006 - 08/2002
4	Neoplasms (Cancer) 01/2024 - 12/2016
4	Body Weight (Weight, Body) 10/2023 - 11/2006
4	Pain (Aches) 01/2021 - 12/2005
3	Infections 01/2024 - 10/2004
3	Breast Neoplasms (Breast Cancer) 12/2020 - 01/2009
2	Hyperlipidemias (Hyperlipidemia) 12/2023 - 01/2022
2	Ascites 10/2023 - 11/2022
2	Hypertension (High Blood Pressure) 06/2023 - 10/2006
2	Asthma (Bronchial Asthma) 06/2023 - 01/2003
2	Fibrosis (Cirrhosis) 06/2020 - 01/2012
2	Drug-Related Side Effects and Adverse Reactions 01/2020 - 10/2017
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2018 - 11/2016
2	Atrial Fibrillation 11/2018 - 01/2017
2	Carcinoma (Carcinomatosis) 10/2017 - 10/2004
2	Hyperuricemia 01/2016 - 01/2014
2	Liver Diseases (Liver Disease) 01/2016 - 01/2014
2	Hepatitis C 01/2013 - 10/2004
2	Hypokalemia 07/2007 - 10/2006
2	Hemolytic Anemia 01/2006 - 10/2004
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 12/2023
1	Hepatitis B 12/2023
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 10/2023
1	Rhinitis 06/2023
1	Sleep Initiation and Maintenance Disorders (Insomnia) 06/2023
1	Cough 06/2023
1	Hyperemia 06/2023
1	Dysuria 06/2023
1	Necrotizing Fasciitis 05/2023
1	Disseminated Intravascular Coagulation 05/2023
1	Stomach Neoplasms (Stomach Cancer) 11/2022
1	Neoplasm Metastasis (Metastasis) 11/2022
1	Cancer Pain 10/2022
1	Opioid-Induced Constipation 10/2022
1	Colonic Neoplasms (Colon Cancer) 12/2021
1	Stomach Ulcer (Gastric Ulcer) 08/2021
1	Aplastic Anemia (Anemia, Hypoplastic) 05/2021
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 05/2021
1	Hypoalbuminemia 01/2021
1	Constipation 01/2021
1	Stomatitis 01/2021
1	Compartment Syndromes 11/2020

Drug/Important Bio-Agent (IBA)

12	Flecainide (Tambocor)FDA LinkGeneric 06/2020 - 08/2002
5	Glycyrrhizic Acid (Glycyrrhizin)IBA 01/2021 - 10/2006
3	Tacrolimus (Prograf)FDA LinkGeneric 08/2021 - 08/2002
3	Proton Pump InhibitorsIBA 08/2021 - 10/2004
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2018 - 11/2016
3	Ribavirin (Virazole)FDA LinkGeneric 01/2006 - 04/2004
2	Rituximab (Mabthera)FDA Link 01/2024 - 12/2023
2	DNA (Deoxyribonucleic Acid)IBA 12/2023 - 01/2012
2	Lipoproteins (Lipoprotein)IBA 12/2023 - 01/2022
2	RamucirumabIBA 10/2023 - 11/2022
2	Immunoglobulin G (IgG)IBA 10/2023 - 11/2022
2	Monoclonal AntibodiesIBA 10/2023 - 11/2022
2	Oral SpraysIBA 01/2021 - 10/2017
2	1- (4- chlorobenzoyl)- 3- (2- (1H- imidazol- 1- yl)- 2- oxoethyl)- 5- methoxy- 2- methyl- 1H- indoleIBA 01/2021 - 10/2017
2	Analgesics (Analgesic Drugs)IBA 01/2021 - 10/2017
2	Indomethacin (Indometacin)FDA LinkGeneric 01/2021 - 10/2017
2	Lapatinib (GW572016)FDA Link 12/2020 - 12/2016
2	Anti-Arrhythmia AgentsIBA 06/2020 - 10/2007
2	EnzymesIBA 11/2016 - 08/2002
2	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 07/2009 - 11/2006
2	Rabeprazole (Aciphex)FDA Link 01/2009 - 10/2004
2	Hemoglobins (Hemoglobin)IBA 01/2006 - 04/2004
2	InterferonsIBA 01/2006 - 04/2004
1	entecavir FDA Link 12/2023
1	nasIBA 12/2023
1	NucleosidesIBA 12/2023
1	AntigensIBA 12/2023
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 12/2023
1	Pseudoephedrine FDA LinkGeneric 06/2023
1	Sympathomimetics (Sympathomimetic Amines)IBA 06/2023
1	Ephedrine FDA LinkGeneric 06/2023
1	AlkaloidsIBA 06/2023
1	Ephedrae herbaIBA 06/2023
1	Indicators and Reagents (Reagents)IBA 05/2023
1	Dacarbazine (DIC)FDA LinkGeneric 05/2023
1	NivolumabIBA 11/2022
1	naldemedineIBA 10/2022
1	Opioid Analgesics (Opioids)IBA 10/2022
1	LipidsIBA 01/2022
1	Triglycerides (Triacylglycerol)IBA 01/2022
1	Amiodarone (Amiodarona)FDA LinkGeneric 01/2022
1	Bevacizumab (Avastin)FDA Link 12/2021
1	Thrombopoietin ReceptorsIBA 05/2021
1	eltrombopag FDA Link 05/2021
1	Inosine Triphosphate (ITP)IBA 05/2021
1	BilirubinIBA 01/2021
1	Propafenone (Rythmol)FDA LinkGeneric 12/2020
1	5-hydroxypropafenoneIBA 12/2020

Therapy/Procedure

4	Drug Therapy (Chemotherapy) 01/2024 - 01/2014
4	Therapeutics 10/2017 - 04/2004
3	Kampo Medicine (Kampo) 06/2023 - 01/2016
2	Radiotherapy 01/2021 - 10/2017
1	Hematopoietic Stem Cell Transplantation 01/2024
1	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 12/2023
1	Surgical Amputation (Amputations) 05/2023
1	Aftercare (After-Treatment) 01/2021